期刊
CANCER DISCOVERY
卷 5, 期 11, 页码 1130-1132出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-15-0945
关键词
-
类别
资金
- NCI NIH HHS [1U01CA168394, U01 CA168394, U54CA112970, U54 CA112970] Funding Source: Medline
- NHGRI NIH HHS [U54 HG008100, U54HG008100] Funding Source: Medline
The major challenge underlying the emerging precision medicine initiative is to make links between cancer subsets and drugs that can be used to guide treatment of individual patients, leading to improved outcomes and decreased toxicity. Seashore-Ludlow and colleagues support this effort by reporting measurements of responses of 664 adherent cancer cell lines to 70 FDA-approved drugs, 100 experimental compounds, and 311 small-molecule probes. They use a novel Annotated Cluster Multidimensional Enrichment algorithm to identify drug mechanisms of action, molecular markers of response, responsive cancer subtypes, and compounds that produce synergistic cell inhibition. (C)2015 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据